DOCSLIB.ORG

Biovendor Product Catalogue 2014 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biovendor Product Catalogue 2014 2015 BioVendor Research and Diagnostic Products, a.s. European Union: USA, Canada and Mexico: China – Mainland Office: Karasek 1767/1 BioVendor GmbH BioVendor, LLC BioVendor Laboratories Ltd. 621 00 Brno Im Neuenheimer Feld 583 128 Bingham Rd., Suite 1300 Room 2917, 29/F, R & F Ying Feng Plaza No.2 CZECH REPUBLIC D-69120 Heidelberg, GERMANY Asheville, NC 28806, USA Huaqiang road, Pearl River New Town, Guangzhou, CHINA Phone: +49 6221 433 9100 Phone: +1-800-404-7807 Phone: +86 20 38065519 Phone: +420 549 124 185 Fax: +49 6221 433 9111 +1-828-575-9250 Fax: +86 20 38065529, e-mail: [email protected] Fax: +420 549 211 460 e-mail: [email protected] Fax: +1-828-575-9251 e-mail: [email protected] e-mail: [email protected] China – Hong Kong Office: BioVendor GesmbH BioVendor Laboratories Ltd. Nußdorfer Straße 20/10 Room 4008, Hong Kong Plaza, No.188 1190 Vienna, AUSTRIA Connaught Road West, Hong Kong, CHINA Phone: +43 1 89090 25 Phone: +852 28030523 Fax: +43 1 89090 2515 www.biovendor.com Fax: +852 28030525, e-mail: [email protected] e-mail: [email protected] BIOVENDOR R&D PRODUCTS Our Products and Services ANTIBODIES Products The company superiority in the preparation of recombinant proteins enables us to raise excellent mouse monoclonal and rabbit and sheep polyclonal antibodies. We provide the scientific community with unique research tools helping them to obtain original data that have resulted in many publications. BioVendor’s monoclonal and polyclonal antibodies have become the backbones of many of our as well as other companies’ immunodiagnostics. PROTEINS Products The combination of perfectly posttranslationally processed recombinant proteins produced in cell line HEK 293 and robust E. coli recombinant production systems is crucial for accelerated development of new recombinant proteins. Together with our capability to isolate natural proteins from human or animal body fluids, BioVendor can fulfill the needs of scientists within our selected fields. IMMUNOASSAYS Products BioVendor’s competitive advantage is its independence from external sources of antibodies and calibrators in the development of immunodiagnostics. To date, we have developed and launched independently over 60 ELISA kits and 50 immunoassays are in the product pipeline. Many others came via technological transfer. Our kits are used in research and clinical labs of more than 60 countries including such demanding and competitive markets as the USA, EU countries and Japan. Service BATS The BioVendor Analytical Testing Service (BATS) offers customer’s sample analysis with our immunoassays which are fully validated for clinical studies. Our advantage is that our personnel is skilled in immunoassay development and we utilize their detailed understanding of the assay performance. This allows us to modify our existing assays to unusual types of matrices. We guarantee full sample traceability, accuracy and confidentiality. Service MULTIPLEX BioVendor provides Custom Bio-Plex® Multianalyte Determination Service using market leading multianalyte system providers such as Bio-Rad, R&D Systems, Merck Millipore and others. Save your personnel and laboratory capacities, time and money and get maximum analytical information out of minimum sample volume at a minimal expense on personnel, lab instrumentation and reagents. BioVendor enables you to quantitate up to 100 different analytes in a drop of sample, giving you the power to understand complex relationships among proteins in normal and disease states. BIOMEDICAL SPECIMEN BANK Products Provides various types of biological samples along with corresponding panels of data including analytical parameters, anthropometric variables and clinical information for the diagnostic industry, assay manufacturers and researchers. Our expanding portfolio of panels covers both physiological and pathological conditions. Samples are stored at -150°C, supplied on dry ice as 0.105 ml serum, urine or other body fluid, assorted in 96 microplate-format boxes. Inside this catalog, please find examples of panels we provide as well as some examples of data related to them. Dear Customer, We are proud to introduce the 2014/2015 BioVendor Research and Diagnostic Products Catalog. This new edition of the catalog is covering the entire portfolio of our products and services designed to help you, the life science, diagnostic and biotech communities, advance your research. As new products and services are released within the lifespan of this catalog, we will print updated brochures on a regular basis. You are welcome to contact our Marketing/Sales department, which will provide you with new information in a timely manner and/ or send you the latest updates. Enjoy our accommodating responses to your demands including customized products, individual production of bulk quantities, and special packaging and product testing – all designed to meet your needs. We thank you for the increasing interest in our products, and we commit ourselves to continually bringing innovative research tools to the world of life science. Do you wish to be involved in the exciting process of development and marketing of new products? Are you interested in learning more about us? Your initiatives, ideas and inquires are gratefully welcome. Yours faithfully, Viktor Růžička, MD CEO LET´S TALK! Tel: + 420 549 124 185 E-mail: [email protected] Web: www.biovendor.com 3 BIOVENDOR R&D PRODUCTS Our History and Commitment BioVendor – Laboratorni Medicina a.s. established its Research and Diagnostic Products Division as an emerging innovative biotech company in the South Moravian part of the Czech Republic, European Union in 1995. BioVendor R&D Products’ mission is to provide researchers and medical experts with top-quality immunodiagnostics and related biochemicals – antibodies and recombinant proteins, aimed mainly at: obesity/metabolic syndrome/diabetes, cardiovascular physiology, kidney injury, bone metabolism/osteoporosis, immune response/infection/inflammation, neural tissue damage markers, and animal model research. BioVendor’s strength stems from its full control over the whole R&D process conducted by continuously educated researchers in new, fully-equipped labs. Our customers include the world’s top-ranking scientific institutions, pharmaceutical and biotech companies and clinical laboratories. As a result, we have recently opened branches in Germany, the USA and China, to expedite distribution, improve our customer service and to strengthen the existing worldwide network of BioVendor’s distributors. BioVendor has established its Quality Management system since 1999 – being ISO-certified in accordance with the regulations of ISO 9001, ISO 13485 and ISO 14001. BioVendor has become internationally recognized for its achievements in rapid launching of high-quality products – resulting in the development of biomarkers for early detection of common diseases associated with postindustrial societies. We are proud that BioVendor’s Leptin ELISA, the first commercial ELISA (1998), opened the door to investigations of fat tissue hormones and that our Adiponectin ELISA, the first kit marked as IVD in the EU, helped make routine clinical testing of this hormone possible. BioVendor’s motivated team is accustomed to being in the forefront of novel research tool development. 1994 – Leptin, the first fat tissue hormone described 1998 – the first commercial Leptin ELISA – released by BioVendor 2001 – Resistin, possible link between diabetes and obesity described 2002 – the most often referred Resistin ELISA – released by BioVendor 2003 – BioVendor’s Adiponectin ELISA 2005 – the first Adipocyte FABP ELISA – developed by BioVendor 2006 – the first commercial Clusterin ELISA – released by BioVendor 2007 – the first commercial ZA2G ELISA – released by BioVendor 2008 – the first commercial FGF-21 ELISA – released by BioVendor 2009 – the first commercial SP-A ELISA – released by BioVendor 2010 – BioVendor was granted by the European patent EP 1 904 082 for Adipocyte FABP ELISA 2011 – the first commercial Serum Uromodulin ELISA – patent pending 2012 – the first commercial Lecithin-Cholesterol Acyltransferase ELISA – released by BioVendor 2013 – the first commercial Pancreatic-Derived Factor ELISA – released by BioVendor These and many other achievements are the fruit of the unmatched dedication of our team members as well as BioVendor’s creative leadership and boldness in developing new research projects for novel biomarkers shortly after the first interesting results have been published. 4 Purchasing information and conditions of sale Following the licence agreements made and entered into by BioVendor and its suppliers or licensors, the sale of some products is restricted to certain areas. Since it is not possible to specify this for each product, we cannot guarantee that all products stated in the catalogue are available in all countries. Please check their availability at [email protected]. Ordering Orders can be placed either by e-mail, fax, phone or post. Please use our website at www.biovendor.com to order online. Distribution Network BioVendor’s products can be ordered all over the world either directly from BioVendor headquarters, BioVendor subsidiaries or from our network of local distributors. Your orders will be forwarded to the office corresponding to your market area. Please contact either BioVendor’s sales department or consult our website for details. Required Information • Purchase order number (for credit card numbers, please enquire) • Product catalog number and
Load more

Recommended publications
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • A1348-Anti-PSA Mab(4A5D10)
    BioVision 06/17 For research use only Anti-PSA Antibody (4A5D10) Capture CATALOG NO: A1348-1000 Detection A1345 A1346 A1347 A1348 A1349 AMOUNT: 1 mg (5B10D4) (8A9B8) (1G9G8) (4A5D10) (1A7D4) A1345 +++ ++ ++ +++ ALTRERNATE NAMES: Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, Semenogelase, APS (5B10D4) A1346 - - +++ - IMMUNOGEN: Human total PSA purified from semenal plasma. (8A9B8) CLONALITY: Monoclonal A1347 - +++ - ++ (1G9G8) CLONE: 4A5D10 A1348 - - - - HOST/ISOTYPE: Mouse IgG2a, κ (4A5D10) PURIFICATION: Protein A purification A1349 ++ - ++ ++ (1A7D4) FORM: Liquid The above Data was achieved by Sandwich ELISA. ‘+’ means reaction and ‘-‘means CONCENTRATION: 0.5 mg/ml no reaction. The number of ‘+’ represents reaction intensity. FORMULATION: In PBS buffer, pH 7.4, containing 0.02% sodium azide A STORAGE CONDITIONS: For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles. SPECIFICITY: PSA monoclonal antibodies (5B10D4, 8A9B8, 1G9G8, 4A5D10 and 1A7D4) recognize total PSA, free PSA and ACT- PSA Complex (Prostate Specific Antigen / a-1 Antichymotrypsin Complex). DESCRIPTION: Prostate-specific antigen (PSA) is also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen. It is a serine protease enzyme produced by the cells of the prostate gland. Most of PSA in the blood which is bound to serum proteins is known as total PSA, while a small amount which is not protein bound to is called free PSA. PSA liquifies the semen in the seminal coagulum and allows sperm to swim freely. PSA is often elevated in the presence of prostate cancer and in other prostate disorders. A blood test to measure PSA is considered to be the most effective test currently available for the early detection of prostate cancer.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • Accession Lit 2DEMS L CMS1 L CMS2 T Otal Accessions T
    Supplemental Data Table from "The Human Plasma Proteome: A Non-Redundant List Developed by Combination of Four Separate Sources" by N. Leigh Anderson, Malu Polanski, Rembert Pieper, Tina Gatlin, Radhakrishna S. Tirumalai, Thomas P. Conrads, Timothy D. Veenstra, Joshua N. Adkins, Joel G. Pounds, Richard Fagan, and Anna Lobley (Molecular and Cellular Proteomics, in press (Feb 2004). The table lists all 1175 non-redundant accessions, of which only 195 are detected in more than one source (total_sources > 1). Since a substantial number of the 980 accessions found in only one data set could result from MS identification errors, the reader should view these as candidate plasma components subject to confirmation. CMS1 CMS2 otal_accessions otal_sources Accession Lit 2DEMS L L T T Signal TM Description P29312 0 1 0 0 1 1 no 0 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein- 1) (KCIP-1) (Factor activating exoenzyme S) (FAS). Q9C0C2 0 1 0 0 1 1 no 0 182 kda tankyrase 1-binding protein. P00973 1 0 0 0 1 1 no 0 2'-5'-oligoadenylate synthetase 1 (EC 2.7.7.-) ((2- 5')oligo(A) synthetase 1) (2-5A synthetase 1) (p46/p42 OAS) (E18/E16). P29728 1 0 0 0 1 1 no 0 2'-5'-oligoadenylate synthetase 2 (EC 2.7.7.-) ((2- 5')oligo(A) synthetase 2) (2-5A synthetase 2) (p69 OAS / p71 OAS) (p69oas / p71oas). NP_006178 0 0 0 1 1 1 no 0 2'-5'oligoadenylate synthetase 3; 2'-5'-oligoadenylate synthetase 3 P35998 0 1 0 0 1 1 no 0 26S protease regulatory subunit 7 (MSS1 protein).
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Prostate Specific Antigen Antibody
    Product Datasheet Prostate Specific Antigen Antibody Catalog No: #49127 Package Size: #49127-1 50ul #49127-2 100ul Orders: [email protected] Support: [email protected] Description Product Name Prostate Specific Antigen Antibody Host Species Rabbit Clonality Monoclonal Clone No. SD07-45 Purification ProA affinity purified Applications WB, ICC/IF, IHC Species Reactivity Hu Immunogen Description recombinant protein Other Names antigen, prostate-specific antibody APS antibody Gamma seminoprotein antibody Gamma-seminoprotein antibody hK3 antibody Kallikrein 3 antibody Kallikrein related peptidase 3 antibody Kallikrein-3 antibody KLK 3 antibody KLK2A1 antibody Klk3 antibody KLK3_HUMAN antibody P-30 antigen antibody P30 antigen antibody Prostate-specific antigen antibody Psa antibody Semenogelase antibody Seminin antibody Accession No. Swiss-Prot#:P07288 Calculated MW 34 kDa Formulation 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. Storage Store at -20°C Application Details WB: 1:1,000IHC: 1:50-1:200ICC: 1:50-1:200 Images Immunohistochemical analysis of paraffin-embedded mouse prostate tissue using anti-PSA antibody. Counter stained with hematoxylin. Address: 8400 Baltimore Ave. Suite 302 College Park MD 20740 USA http://www.sabbiotech.com 1 ICC staining PSA in PC-3M cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. Background Prostate specific antigen (PSA), also designated γ-seminoprotein, seminin, p30 antigen, semenogelase, and kallikrein 3 (KLK3), was first identified as a glycoprotein in human seminal plasma. PSA was determined by sequence similarity to be a member of the kallikrein subfamily of trypsin proteases. PSA is a serine protease that hydrolyzes the major human seminal protein, the seminal plasma mobility inhibitor precursor, or semenogelin I (SPMIP or SgI), which leads to semen liquification.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • PSA (A67-B/E3): Sc-7316
    SANTA CRUZ BIOTECHNOLOGY, INC. PSA (A67-B/E3): sc-7316 BACKGROUND STORAGE Prostate specific antigen (PSA), also designated g-seminoprotein, seminin, p30 Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of antigen, semenogelase, and kallikrein 3 (KLK3), was first identified as a gly- shipment. Non-hazardous. No MSDS required. coprotein in human seminal plasma. PSA was determined by sequence simi- larity to be a member of the kallikrein subfamily of trypsin proteases. PSA DATA is a serine protease that hydrolyzes the major human seminal protein, the A B seminal plasma mobility inhibitor precursor, or semenogelin I (SPMIP or SgI), AB which leads to semen liquification. PSA production and expression are highest 92 K – in normal, benign hyperplastic and cancerous tissues of the prostate, although PSA has also been detected in accessory male sex glands and in breast can- 52 K – PSA cer. PSA has been identified as an aid in the early detection of prostate cancer and is a commonly used tumor marker. 37 K – CHROMOSOMAL LOCATION PSA (A67-B/E3): sc-7316. Western blot analysis of PSA PSA (A67-B/E3): sc-7316. Immunoperoxidase staining Genetic locus: KLK3 (human) mapping to 19q13.33. in purified non-complexing human PSA (A) and purified of formalin-fixed, paraffin-embedded human prostate human PSA-ACT complex (B). tissue cytoplasmic staining (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human SOURCE prostate tissue showing cytoplasmic staining of glandular cells (B). PSA (A67-B/E3) is a mouse monoclonal antibody raised against amino acids 1-261 representing full length PSA p30 of human origin.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636,359 B2 Kenyon Et Al
    USOO9636359B2 (12) United States Patent (10) Patent No.: US 9,636,359 B2 Kenyon et al. (45) Date of Patent: May 2, 2017 (54) PHARMACEUTICAL COMPOSITION FOR (52) U.S. Cl. TREATING CANCER COMPRISING CPC ............ A61K 33/04 (2013.01); A61 K3I/095 TRYPSINOGEN AND/OR (2013.01); A61K 3L/21 (2013.01); A61K 38/47 CHYMOTRYPSINOGEN AND AN ACTIVE (2013.01); A61K 38/4826 (2013.01); A61 K AGENT SELECTED FROMA SELENUM 45/06 (2013.01) (58) Field of Classification Search COMPOUND, A VANILLOID COMPOUND None AND A CYTOPLASMC GLYCOLYSIS See application file for complete search history. REDUCTION AGENT (75) Inventors: Julian Norman Kenyon, Hampshire (56) References Cited (GB); Paul Rodney Clayton, Surrey U.S. PATENT DOCUMENTS (GB); David Tosh, Bath and North East Somerset (GB); Fernando Felguer, 4,514,388 A * 4, 1985 Psaledakis ................... 424/94.1 Glenside (AU); Ralf Brandt, Greenwith 4,978.332 A * 12/1990 Luck ...................... A61K 33,24 (AU) 514,930 (Continued) (73) Assignee: The University of Sydney, New South Wales (AU) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this KR 2007/0012040 1, 2007 patent is extended or adjusted under 35 WO WO 2009/061051 ck 5, 2009 U.S.C. 154(b) by 0 days. (21) Appl. No.: 13/502,917 OTHER PUBLICATIONS (22) PCT Fed: Oct. 22, 2010 Novak JF et al. Proenzyme Therapy of Cancer, Anticanc Res 25: 1157-1178, 2005).* (86) PCT No.: PCT/AU2O1 O/OO1403 (Continued) S 371 (c)(1), (2), (4) Date: Jun. 22, 2012 Primary Examiner — Erin M Bowers (74) Attorney, Agent, or Firm — Carol L.
    [Show full text]
  • PSA Antibody [SPM352] Cat
    PSA Antibody [SPM352] Cat. No.: 34-120 PSA Antibody [SPM352] Specifications HOST SPECIES: Mouse SPECIES REACTIVITY: Human Prostate specific antigen from human sperm plasma was used as the immunogen for this IMMUNOGEN: PSA antibody. TESTED APPLICATIONS: Flow, IF, IHC Flow Cytometry: 0.5-1 ug/million cells in 0.1ml Immunofluorescence: 0.5-1 ug/ml Immunohistochemistry (FFPE): 0.25-0.5 ug/ml for 30 min at RT (1) Prediluted format: incubate for 30 min at RT (2) APPLICATIONS: The optimal dilution of the PSA antibody for each application should be determined by the researcher. 1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. 2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. Properties September 28, 2021 1 https://www.prosci-inc.com/psa-antibody-spm352-34-120.html PURIFICATION: Protein G affinity chromatography CLONALITY: Monoclonal ISOTYPE: IgG1, kappa CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: PBS with 0.1 mg/ml BSA and 0.05% sodium azide CONCENTRATION: 0.2 mg/mL STORAGE CONDITIONS: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles. Additional Info OFFICIAL SYMBOL: KLK3 Prostate-specific antigen, PSA, Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, ALTERNATE NAMES: Semenogelase, KLK3, APS GENE ID: 354 USER NOTE: Optimal dilutions for each application to be determined by the researcher Background and References Recognizes a single protein of 33-34kDa, identified as the prostate specific antigen (PSA).
    [Show full text]
  • WO 2015/021058 A2 12 February 2015 (12.02.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/021058 A2 12 February 2015 (12.02.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12Q 1/37 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/049805 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 5 August 2014 (05.08.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/862,363 5 August 2013 (05.08.2013) US kind of regional protection available): ARIPO (BW, GH, 61/987,5 18 2 May 2014 (02.05.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: GREENLIGHT BIOSCIENCES, INC. TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [US/US]; 200 Boston Avenue, Suite 3100, Medford, MA EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 02155 (US).
    [Show full text]